Trial Profile
A Randomized, Double-blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence - the PATHWay Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms PATHWay
- 02 Mar 2023 Planned End Date changed from 1 Jun 2023 to 25 Jun 2025.
- 02 Mar 2023 Planned primary completion date changed from 20 Jun 2022 to 20 Jun 2025.
- 07 Jan 2022 Planned primary completion date changed from 20 Dec 2021 to 20 Jun 2022.